Mentions
Extended reach
Total likes
Video views
AI synopsis
Many posts highlight the potentially concerning range of lean mass loss associated with GLP-1 therapies, with phrases like '40-60% of total weight lost can be muscle,' reflecting shared apprehensions about the effects on muscle health. The tone of these discussions often blends concern and a critical assessment of existing data, suggesting that while there is agreement on the therapeutic benefits, there's also a keen interest in the long-term consequences and strategies to mitigate muscle loss.
The general tone across posts reflects a consensus about the need for attention to lean body mass changes when using GLP-1 therapies.
Participants show high curiosity, often discussing specific aspects of the publication that resonate with their experiences and knowledge in the field.
While many posts express agreement, there is moderate exploration of the methodology and implications of the publication, suggesting that participants want to dive deeper into the topic.
Users perceive the findings as having a significant effect on the understanding of weight loss therapies and their broader implications for patient care.
A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #obesity #weightloss https://t.co/jVeiBj9YQK
Review Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Important to improve muscle health with weight loss interventions https://t.co/FeDPleB6pR https://t.co/BVRDLguBFo
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/zWyTQUAkbd https://t.co/LmA45a6xKL
When you lose weight, you lose both fat and lean body mass. Weight loss by diet alone results in a little less muscle loss, but the GLP1-RA drugs are in line with bariatric surgery and not all that different https://t.co/ItK0bxgEIz https://t.co/FOyVabQUWw https://t.co/p71NYl7uHR
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/9kJADZNWeR
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies "based on contemporary evidence with the addition of MRI-based studies, skeletal muscle changes with GLP-1RA treatments appear to be adaptive" https://t.co/IJSdxUzw43 https://t.co/LIJd70SmGf
Considering GLP-1s for weight loss? This video explains the risk of muscle loss associated with medications like Ozempic and Semaglutide. Learn how significant weight loss can lead to lean mass changes and explore…
Wondering about GLP-1 medications like Wegovy or Ozempic? This video explains their impact on weight loss and muscle health. We'll discuss the benefits, side effects, and safety risks while providing nutrition tips to…
Ozempic and Mounjaro can significantly aid in treating obesity and diabetes. However, without proper supervision, risks such as vitamin deficiencies and loss of lean body mass may arise. This video discusses the…
@Medecin2famille @docdu16 @Dermatopoullos @Fraslin Jusqu'à 40-60% de la perte de poids peut être du muscle https://t.co/JIjX2ZaSzK
But 40 to 60% of total weight lost with glp1 agonists is lean mass (muscle)
RT @AponiaAnalytics:
RT @AponiaAnalytics:
RT @AponiaAnalytics:
RT @AponiaAnalytics:
RT @AponiaAnalytics:
RT @AponiaAnalytics:
RT @AponiaAnalytics:
RT @AponiaAnalytics:
RT @AponiaAnalytics:
RT @AponiaAnalytics:
RT @AponiaAnalytics:
Meta-analyses show GLP‑1 weight loss usually causes lean mass loss similar to other rapid weight loss methods (~25%). But in some studies, semaglutide and tirzepatide have shown up to 40% lean mass loss. https://t.co/GaQHZzHQsL https://t.co/nOYgrhynFk https://t.co/9Ibz8KWpWW https://t.co/klUDCotOQH
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Muscle tissue/mass amounts are assumed. "Body composition metrics such as muscle mass or lean mass, by contrast, are considered safety endpoints, which require far smaller cohorts
https://t.co/zVQmwU1D9d
RT @statesdj: When you lose weight, you lose both fat and lean body mass. Weight loss by diet alone results in a little less muscle loss, b…
When you lose weight, you lose both fat and lean body mass. Weight loss by diet alone results in a little less muscle loss, but the GLP1-RA drugs are in line with bariatric surgery and not all that different https://t.co/ItK0bxgEIz https://t.co/FOyVabQUWw https://t.co/p71NYl7uHR
When you lose weight, you lose both fat and lean body mass. Weight loss by diet alone results in a little less muscle loss, but the GLP-RA drugs are in line with bariatric surgery and not all that different https://t.co/ItK0bxgEIz https://t.co/XNslVCSwKb https://t.co/p71NYl7uHR
@AJA_Cortes We don't have long-term data on GLP-1, do we? Source: PubMed Title: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies URL: http://pubmed.ncbi.nlm.nih.govDescription: The summary highlights the heterogeneity in reported effects of
@WolverineDavis @AbudBakri Source: PubMed Title: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies URL: https://t.co/pmNCQmMKGg Description: The summary highlights the heterogeneity in reported effects of GLP-1-based therapies on lean mass changes in clinical
@R_HatthornHaley @BigWeekendShow @NBSaphierMD https://t.co/SqbuisIjUy.
Older pts already have low muscle reserves. GLP 1s further deplete these as they lead to “reductions in lean mass range between 40% and 60% as a proportion of total weight lost” https://t.co/wp97IKJgm9 So hypothetically you may be looking slimmer but the quality of life post
This paper suggests lean mass percent doesn't always correlate w/ muscle. So organ size could be a problem instead. I think Bryan measures those. "Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies" [JUN 2024] https://t.co/vZUXp9iXSA
@topher_wil @DrNadolsky Actually, not exactly what happens this is a great article explains exactly what happens Also, please remember that obesity is a multifaceted disorder that sometimes requires medical or even surgical therapy with the help of a certified physician https://t.co/EE3LkXlAsh
RT @maymuhareb: Changes in lean body mass with glucagon-like peptide-1-based therapies https://t.co/E5x5SVAfvh
Full article https://t.co/ojKc5KlCQu
Changes in lean body mass with glucagon-like peptide-1-based therapies https://t.co/E5x5SVAfvh
@MrDumbBitch https://t.co/lj0tq1G9YC https://t.co/n0Z0tUeFfK
Cambios en la masa corporal magra con terapias basadas en el péptido similar al glucagón-1 y formas d epoder mitigarlo https://t.co/bPKlnR9xkt
https://t.co/NfASbv2pqh
RT @kamleshkhunti: Review Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Important to i…
RT @kamleshkhunti: Review Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Important to i…
RT @kamleshkhunti: Review Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Important to i…
RT @kamleshkhunti: Review Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Important to i…
RT @kamleshkhunti: Review Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Important to i…
Review Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Important to improve muscle health with weight loss interventions https://t.co/FeDPleB6pR https://t.co/BVRDLguBFo
RT @kamleshkhunti: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/zWyTQUAkb…
RT @kamleshkhunti: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/zWyTQUAkb…
RT @kamleshkhunti: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/zWyTQUAkb…
RT @kamleshkhunti: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/zWyTQUAkb…
RT @kamleshkhunti: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/zWyTQUAkb…
RT @kamleshkhunti: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/zWyTQUAkb…
RT @kamleshkhunti: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/zWyTQUAkb…
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/zWyTQUAkbd https://t.co/LmA45a6xKL
RT @CraigAGoodman1: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/9kJADZNWeR
RT @CraigAGoodman1: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/9kJADZNWeR
RT @DanielJDrucker: A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #…
RT @DrMyohead: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies "based on contemporary evi…
Should we be concerned about losing muscle mass when using GLP-1 therapies such as Ozempic? Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies - https://t.co/rAQuFfdeBb Introduction: Are you or someone you know on GLP-1-based https://t.co/42FdvEHNHv
RT @DanielJDrucker: A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #…
RT @DanielJDrucker: A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #…
RT @CraigAGoodman1: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/9kJADZNWeR
RT @DanielJDrucker: A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #…
RT @Office_j: 【備忘】 DOM誌にGLP-1ベース減量と除脂肪体重に関するレビュー。体重減に伴う除脂肪体重減少は食事療法や減量手術と同等だが、筋肉の「質」や「機能」に対する検討も必要との見解。 https://t.co/ExqTjvRKIG
【備忘】 DOM誌にGLP-1ベース減量と除脂肪体重に関するレビュー。体重減に伴う除脂肪体重減少は食事療法や減量手術と同等だが、筋肉の「質」や「機能」に対する検討も必要との見解。 https://t.co/ExqTjvRKIG
RT @CraigAGoodman1: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/9kJADZNWeR
RT @CraigAGoodman1: Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/9kJADZNWeR
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies "based on contemporary evidence with the addition of MRI-based studies, skeletal muscle changes with GLP-1RA treatments appear to be adaptive" https://t.co/IJSdxUzw43 https://t.co/LIJd70SmGf
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies https://t.co/9kJADZNWeR
RT @DanielJDrucker: A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #…
Nice review, worth a read. Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies https://t.co/h2M0WCH7AO
RT @DanielJDrucker: A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #…
RT @DanielJDrucker: A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #…
RT @DanielJDrucker: A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #…
RT @DanielJDrucker: A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #…
RT @DanielJDrucker: A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #…
A next frontier for GLP-1 medicines-lean mass, how big will the problem be, what are the best approaches to mitigate? #obesity #weightloss https://t.co/jVeiBj9YQK